These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27357251)

  • 1. [Hemolytic kidney failure and transient ischemic attack in a 32-year-old female].
    Anders R; Grohmann M; Lindner TH; Bergmann C; Halbritter J
    Internist (Berl); 2016 Oct; 57(10):1022-1028. PubMed ID: 27357251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
    Vaisbich MH; Henriques Ldos S; Watanabe A; Pereira LM; Metran CC; Malheiros DA; Modanez F; Silva JD; Vieira S; Macedo AC; Massarope B; Furusawa EA; Schvartsman BG
    J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.
    Andries G; Karass M; Yandrapalli S; Linder K; Liu D; Nelson J; Pawar R; Chugh S
    Exp Hematol Oncol; 2017; 6():4. PubMed ID: 28101432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of eculizumab in a case of pregnancy-associated aHUS].
    Cravero R; Ardissino G; Colageo U; Staffa P; Bruschetta E; Maroni S; Karvela E; Spagarino E; Ruggeri V; Jura R
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
    Belingheri M; Possenti I; Tel F; Paglialonga F; Testa S; Salardi S; Ardissino G
    Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?
    Nester CM; Thomas CP
    Hematology Am Soc Hematol Educ Program; 2012; 2012():617-25. PubMed ID: 23233643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome in children.
    Talarico V; Aloe M; Monzani A; Miniero R; Bona G
    Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
    Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa M; Grinyó JM; Praga M; Torra R; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2013 Jan; 33(1):27-45. PubMed ID: 23364625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.
    Zlamy M; Hofer J; Elias J; Vogel U; Frosch M; Jungraithmayr T; Zimmerhackl LB; Prelog M
    Pediatr Transplant; 2012 Sep; 16(6):E246-50. PubMed ID: 21967634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.
    Sinibaldi S; Guzzo I; Piras R; Bresin E; Emma F; Dello Strologo L
    Pediatr Transplant; 2013 Dec; 17(8):E177-81. PubMed ID: 24118826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
    Williams LA; Marques MB;
    Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.